Thermo Fisher Sells Microbiology Unit to Astorg

Thermo Fisher Scientific (TMO) has reached an agreement to divest its microbiology business to private equity firm Astorg for $1.08 billion as the life sciences company refines its diagnostics portfolio.

This divestiture reflects Thermo Fisher’s strategy to eliminate slower-growth assets while facing challenges from declining post-pandemic demand, allowing the company to concentrate resources on more profitable segments.

Key Takeaways

Thermo Fisher divesting microbiology unit for $1.08 billion cash
Astorg acquiring business that makes infectious disease testing equipment
Move follows broader industry trend of portfolio optimization

Market reaction & context

This transaction occurs as life sciences firms reevaluate their business units in the aftermath of the pandemic surge. Thermo Fisher’s diagnostics division has encountered challenges as COVID-19 testing requirements stabilized, creating pressure to refine its portfolio composition ¹.

The microbiology division produces roughly $300 million in adjusted earnings per year on $1.4 billion in revenue, accounting for approximately one-third of Thermo Fisher’s wider specialty diagnostics segment. The acquisition prices the business at around 3.6 times revenue, consistent with recent diagnostics deals ².

Strategic rationale

This transaction demonstrates Thermo Fisher’s focused capital allocation approach as the organization looks to exit peripheral assets. Earlier in the year, media reports indicated the company was evaluating the potential sale of diagnostics unit components valued at roughly $4 billion ³.

Astorg’s purchase fits with private equity’s increasing focus on healthcare properties with stable cash generation. The Paris-headquartered firm has historically invested in medical technology and pharmaceutical services enterprises throughout Europe ⁴.

Industry consolidation continues

This transaction marks another step in ongoing diagnostic sector deals as organizations streamline their operations. Competitor Becton Dickinson recently revealed plans to spin off its life sciences division, including diagnostics units, demonstrating comparable strategic objectives ⁵.

Simultaneously, Thermo Fisher maintains its expansion in faster-growing sectors through acquisitions, recently announcing an $8.9 billion transaction to purchase clinical trial data company Clario from a consortium led by Astorg and Nordic Capital ⁶.

Financial implications

The microbiology transaction consists of $1.08 billion in cash plus a $50 million seller note. Thermo Fisher anticipates utilizing the proceeds to finance growth investments and decrease debt following recent major acquisitions.

The deal is anticipated to conclude in mid-2026, pending regulatory clearances and standard closing requirements. After completion, the sold unit will function independently under Astorg’s management.

Outlook

This divestiture enables Thermo Fisher to concentrate resources on its primary laboratory products and biopharma services divisions, which present superior growth potential. The company has shown reliable execution of its portfolio refinement approach in recent years.

For Astorg, this acquisition delivers access to the steady diagnostics sector while creating opportunities for operational enhancements and geographic expansion under private equity stewardship.

Not investment advice. For informational purposes only.